Efficacy and safety of chemotherapy after PD-1 inhibitors in patients with non-small cell lung cancer: a retrospective multi-institutional analysis (WJOG10217L)

Efficacy and safety of chemotherapy after PD-1 inhibitors in patients with non-small cell lung cancer: a retrospective multi-institutional analysis (WJOG10217L) - chemotherapy after PD-1 inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029576

Enrollment

240

Registered

2017-10-20

Start date

2017-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically confirmed NSCLC 2. Stage III, IV or recurrence after curative radiotherapy or surgery according to the seventh edition of the TNM classification 3. Previously treated with cytotoxic chemotherapy as a first-line 1) Study arm: treated with nivolumab or pembrolizumab as a second-line and subsequently treated with cytotoxic chemotherapy including docetaxel (with or without ramucirumab), pemetrexed or S-1 as a third-line between December 1, 2015 and July 31, 2017 2) Control arm: treated with cytotoxic chemotherapy including docetaxel (with or without ramucirumab), pemetrexed or S-1 as a second-line between April 1, 2014 and July 31, 2017

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Overall response rate of cytotoxic chemotherapy including docetaxel (with or without ramucirumab), pemetrexed or S-1	—

Secondary

Measure	Time frame
Progression-free survival, overall survival and safety of cytotoxic chemotherapy including docetaxel (with or without ramucirumab), pemetrexed or S-1	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results